Nalaganje...
REGN-EB3: First Approval
REGN-EB3 (INMAZEB(®), Regeneron Pharmaceuticals) is a combination of three fully-human monoclonal antibodies—atoltivimab (REGN3470), maftivimab (REGN3479), and odesivimab (REGN3471) —that target Ebola virus glycoprotein. Based on the results of the PALM study conducted during an Ebola outbreak in th...
Shranjeno v:
| izdano v: | Drugs |
|---|---|
| Glavni avtor: | |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer International Publishing
2021
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7799152/ https://ncbi.nlm.nih.gov/pubmed/33432551 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-020-01452-3 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|